26 results on '"Schey, Stephen A."'
Search Results
2. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
3. RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
4. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
5. Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia – A Single-Institution Experience
6. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
7. Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min
8. Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)
9. A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study
10. Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience
11. RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based Therapy
12. Lenalidomide-Based Treatment for Newly Diagnosed Multiple Myeloma Patients, Ineligible for Transplant: A Healthcare Cost-Impact Analysis in Europe
13. Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3
14. Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)
15. Inhibition Of PI3K Classia Kinases Using GDC0941 Overcomes Protection Of Multiple Myeloma Cells In The Bone Marrow Microenvironment
16. Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance
17. CRM1 Inhibition Abrogates Osteoclast Formation and Bone Resorption Via Inhibition of RANKL-Induced NFκB While Sparing Osteoblastogenesis: Further Therapeutic Implication in Multiple Myeloma
18. CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis
19. Cost-Effectiveness of Lenalidomide in Multiple Myeloma Patients with 1 Prior Therapy in England and Wales,
20. The Wiskott Aldrich Syndrome Protein (WASP) Is Involved in Dexamethasone-Signalling Pathways Leading to Apoptosis of Multiple Myeloma Cells and in Cell Adhesion Mediated Drug Resistance Against Dexamethasone
21. CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma
22. Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI).
23. Hepatocyte Growth Factor Expression in Bone Marrow Microenvironment Is Critical for Progression of MGUS to Myeloma.
24. Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.
25. Mcl-1, Bcl-xL and Cell Cycle Inhibition by GCS-100: A Novel Therapy for Myeloma.
26. Bevacizumab Therapy for POEMS Syndrome.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.